Intrahepatic Cholangiocarcinoma Progression: Prognostic Factors and Basic Mechanisms

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 11 SUPPL., 2009, Pages

  Sirica, Alphonse E ^a   Dumur, Catherine I ^a   Campbell, Deanna J W ^a   Almenara, Jorge A ^a   Ogunwobi, Olorunseun O ^a   Dewitt, Jennifer L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MATRIX METALLOPROTEINASE; MUCIN; PROTEIN CCN; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS;

ANIMALS; BIOLOGICAL MARKERS; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; PROGNOSIS; RODENTIA;

EID: 71849085242     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.08.023     Document Type: Article

References (77)

1. Hammill C.W., and Wong L.L. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 207 (2008) 594-603
2. Khan S.A., Toledano M.B., and Taylor-Robinson S.D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10 (2008) 77-82
3. Blechacz B.R.A., and Gores G.J. Cholangiocarcinoma. Clin Liver Dis 12 (2008) 131-150
4. Briggs C.D., Neal C.P., Mann C.D., et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 45 (2009) 33-47
5. Hirohashi K., Uenishi T., Kubo S., et al. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology 49 (2002) 326-329
6. Yeh C.N., Jan Y.Y., Yeh T.S., et al. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol 11 (2004) 606-611
7. Guglielmi A., Ruzzenente A., Campagnaro T., et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 33 (2009) 1247-1254
8. Matsumura N., Yamamoto M., Aruga A., et al. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94 (2002) 1770-1776
9. Boonla C., Sripa B., Thuwajit P., et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol 11 (2005) 4939-4946
10. Shibahara H., Tamada S., Higashi M., et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39 (2004) 220-229
11. Yeh C.N., Pang S.T., Wu R.C., et al. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. Oncology Reports 21 (2009) 49-56
12. Miwa S., Miyagawa S., Soeda J., et al. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer 94 (2002) 428-434
13. Iguchi T., Aishima S., Taketomi A., et al. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis. Hum Pathol 40 (2009) 174-180
14. Javle M.M., Tan D., Yu J., et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 51 (2004) 1653-1657
15. Sugimachi K., Aishima S., Taguchi K., et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 35 (2001) 74-79
16. Aishima S., Nishihara Y., Iguchi T., et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 21 (2008) 256-264
17. Aishima S., Taguchi K., Terashi T., et al. Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol 16 (2003) 1019-1027
18. Aishima S., Matsuura S., Terashi T., et al. Aberrant expression of laminin gamma 2 chain and its prognostic significance in intrahepatic cholangiocarcinoma according to growth morphology. Mod Pathol 17 (2004) 938-945
19. Li Q., Wang J.M., Liu C., et al. Correlation of aPKC-ι and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 7 (2008) 70-75
20. Aishima S., Kuroda Y., Nishihara Y., et al. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Hum Pathol 38 (2007) 1819-1825
21. Gardini A., Corti B., Fiorentino M., et al. Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Dig Liver Dis 37 (2005) 269-274
22. Harada K., Masuda S., Hirano M., et al. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34 (2003) 857-863
23. Sirica A.E. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 14 (2008) 7033-7058
24. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41 (2005) 5-15
25. Zen Y., Fujii T., Itatsu K., et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44 (2006) 1333-1343
26. Ishikawa A., Sasaki M., Ohira S., et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest 84 (2004) 629-638
27. Higashi M., Yonezawa S., Ho J.J., et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30 (1999) 1347-1355
28. Jan Y.Y., Yeh T.S., Yeh J.N., et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 240 (2004) 89-94
29. Singh A.P., Chaturvedi P., and Batra S.K. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 67 (2007) 433-436
30. Workman H.C., Sweeney C., and Carraway III K.L. The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 69 (2009) 2845-2852
31. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 25 (2009) 279-284
32. Thuwajit P., Chawengrattanachot W., Thuwajit C., et al. Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival. J Gastroenterol Hepatol 23 (2008) 771-778
33. Shirabe K., Shimada M., Kajiyama K., et al. Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery 126 (1999) 842-846
34. Itatsu K., Zen Y., Yamaguchi J., et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol 39 (2008) 710-719
35. Leelawat K., Sakchinabut S., Narong S., et al. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 9 (2009) 30
36. Sedlaczek N., Jia J.D., Bauer M., et al. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 158 (2001) 1239-1244
37. Tanaka S., Sugimachi K., Kameyama T., et al. Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37 (2003) 1122-1129
38. Radaeva S., Ferreira-Gonzalez A., and Sirica A.E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29 (1999) 1453-1462
39. Sirica A.E., Lai G.H., and Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 16 (2001) 363-372
40. Lai G.H., and Sirica A.E. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 20 (1999) 2335-2340
41. Sirica A.E., Lai G.H., Endo K., et al. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 22 (2002) 303-313
42. Lai G.H., Zhang Z., Shen X.N., et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129 (2005) 2047-2057
43. Yeh C.N., Maitra A., Lee K.F., et al. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25 (2004) 631-636
44. Mansuroglu T., Ramadori P., Dudás J., et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab Invest 89 (2009) 562-574
45. Lu J.P., Mao J.Q., Li M.S., et al. In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis. World J Gastroenterol 9 (2003) 590-594
46. Sirica A.E., Zhang Z., Lai G.H., et al. A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47 (2008) 1178-1190
47. Dumur C.I., Almenara J.A., Campbell D.J., et al. Genome-wide gene expression profiling in a novel "patient-like" rat model of intrahepatic cholangiocarcinoma progression closely mimicking the human disease. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009 (2009), AACR, Denver, CO. Philadelphia abstract nr 1432
48. Sithithaworn P., Ando K., Limviroj W., et al. Expression of tenascin in bile duct cancer of hamster liver by combined treatment of dimethylnitrosamine with Opisthorchis viverrini infections. J Helminthol 76 (2002) 261-268
49. Farazi P.A., Zeisberg M., Glickman J., et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66 (2006) 6622-6627
50. Xu X., Kobayashi S., Qiao W., et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116 (2006) 1843-1852
51. Kiguchi K., Carbajal S., Chan K., et al. Constitutive expression of ErbB-2 in gallbladder epithilium results in development of adenocarcinoma. Cancer Res 61 (2001) 6971-6976
52. Hansel D.E., Rahman A., Hidaigo M., et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163 (2003) 217-229
53. Yotsumoto F., Yagi H., Suzuki S.O., et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365 (2008) 555-561
54. Castillo J., Erroba E., Perugorría M.J., et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66 (2006) 6129-6138
55. Yamada M., Ichikawa Y., Yamagishi S., et al. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 14 (2008) 2351-2356
56. Zhang Z.-B., Cai L., Zheng S.-G., et al. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res (2009) [Epub ahead of print]
57. van Golen K.L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?. Expert Opin Ther Targets 10 (2006) 709-721
58. Chuaysri C., Thuwajit P., Paupairoj A., et al. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 21 (2009) 957-969
59. Okabe H., Beppu T., Hayashi H., et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 16 (2009) 2555-2564
60. Worthley D.L., Ruszkiewicz A., Davies R., et al. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 27 (2009) 1463-1468
61. Rygiel K.A., Robertson H., Marshall H.L., et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 88 (2008) 112-123
62. Lee M.-J., Yu G.-R., Yoo H.-J., et al. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology 137 (2009) 1138-1150
63. Su W.C., Shiesh S.C., Liu H.S., et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 46 (2001) 1387-1392
64. Ohira S., Sasaki M., Harada K., et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-α and stromal-derived factor-1 released in stroma. Am J Pathol 168 (2006) 1155-1168
65. Matsumoto K., and Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 119 (2006) 477-483
66. De Wever O., Nguyen Q.-D., Van Hoorde L., et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 18 (2004) 1016-1018
67. Ruan K., Bao S., and Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 66 (2009) 2219-2230
68. Erkan M., Kleeff J., Gorbachevski A., et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132 (2007) 1447-1464
69. Kanno A., Satoh K., Masamune A., et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer 122 (2008) 2707-2718
70. Bao S., Ouyang G., Bai X., et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5 (2004) 329-339
71. Shimonishi T., Miyazaki K., Kono N., et al. Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32 (2001) 302-310
72. Roda O., Ortiz-Zapater E., Martínez-Bosch N., et al. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 136 (2009) 1379-1390
73. Ogasawara S., Yano H., Higaki K., et al. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 20 (2001) 97-113
74. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009) 1457-1461
75. Kawahara N., Ono M., Taguchi K.-I., et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 28 (1998) 1512-1517
76. Aishima S., Taguchi K., Sugimachi K., et al. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. Int J Surg Pathol 10 (2002) 47-56
77. Erkan M., Reiser-Erkan C., Michalski C.W., et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 11 (2009) 497-508